Beijing Tong Ren Tang Chinese Medicine Company Limited
HKEX:3613.HK
8.34 (HKD) • At close November 5, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1,524.945 | 1,731.095 | 1,556.158 | 1,315.346 | 1,432.632 | 1,513.873 | 1,265.994 | 1,084.28 | 970.477 | 761.051 | 613.963 | 333.039 |
| Cost of Revenue
| 477.702 | 580.955 | 436.535 | 362.443 | 419.836 | 435.452 | 349.561 | 289.193 | 289.6 | 218.02 | 193.92 | 96.947 |
| Gross Profit
| 1,047.243 | 1,150.14 | 1,119.623 | 952.903 | 1,012.796 | 1,078.421 | 916.433 | 795.087 | 680.877 | 543.031 | 420.043 | 236.092 |
| Gross Profit Ratio
| 0.687 | 0.664 | 0.719 | 0.724 | 0.707 | 0.712 | 0.724 | 0.733 | 0.702 | 0.714 | 0.684 | 0.709 |
| Reseach & Development Expenses
| 12.208 | 7.699 | 11.273 | 9.462 | 13.512 | 18.546 | 9.581 | 4.273 | 5.155 | 4.844 | 1.312 | 0 |
| General & Administrative Expenses
| 179.029 | 154.457 | 155.312 | 138.861 | 164.824 | 148.326 | 127.293 | 109.611 | 90.08 | 78.369 | 78.571 | 46.712 |
| Selling & Marketing Expenses
| 231.261 | 187.224 | 186.368 | 168.917 | 199.097 | 233.154 | 193.517 | 161.901 | 141.93 | 122.639 | 91.013 | 77.129 |
| SG&A
| 419.267 | 341.681 | 341.68 | 307.778 | 363.921 | 381.48 | 320.81 | 271.512 | 232.01 | 201.008 | 169.584 | 123.841 |
| Other Expenses
| 3.651 | -9.595 | -8.039 | -24.278 | -3.111 | -1.073 | -2.061 | -3.924 | -3.608 | -1.496 | -17.797 | -1.42 |
| Operating Expenses
| 431.475 | 332.086 | 333.641 | 283.5 | 360.81 | 380.407 | 318.749 | 267.588 | 228.402 | 199.512 | 151.787 | 122.421 |
| Operating Income
| 615.768 | 811.575 | 778.46 | 669.403 | 651.986 | 698.014 | 597.684 | 527.499 | 452.475 | 343.519 | 268.256 | 113.671 |
| Operating Income Ratio
| 0.404 | 0.469 | 0.5 | 0.509 | 0.455 | 0.461 | 0.472 | 0.486 | 0.466 | 0.451 | 0.437 | 0.341 |
| Total Other Income Expenses Net
| 75.281 | 14.387 | -0.069 | 16.492 | 37.236 | 22.884 | 13.282 | 4.771 | 4.139 | 11.7 | 3.21 | 3.779 |
| Income Before Tax
| 691.049 | 825.962 | 778.391 | 685.895 | 689.222 | 720.898 | 610.966 | 532.27 | 456.614 | 355.219 | 271.466 | 117.45 |
| Income Before Tax Ratio
| 0.453 | 0.477 | 0.5 | 0.521 | 0.481 | 0.476 | 0.483 | 0.491 | 0.471 | 0.467 | 0.442 | 0.353 |
| Income Tax Expense
| 97.203 | 134.669 | 126.848 | 118.014 | 112.37 | 119.575 | 105.454 | 92.39 | 82.036 | 60.521 | 43.918 | 25.289 |
| Net Income
| 540.393 | 645.875 | 607.838 | 542.456 | 556.118 | 580.72 | 489.967 | 420.315 | 354.249 | 287.124 | 220.001 | 155.935 |
| Net Income Ratio
| 0.354 | 0.373 | 0.391 | 0.412 | 0.388 | 0.384 | 0.387 | 0.388 | 0.365 | 0.377 | 0.358 | 0.468 |
| EPS
| 0.65 | 0.77 | 0.73 | 0.65 | 0.66 | 0.69 | 0.59 | 0.5 | 0.42 | 0.35 | 0.29 | 0.19 |
| EPS Diluted
| 0.65 | 0.77 | 0.73 | 0.65 | 0.66 | 0.69 | 0.59 | 0.5 | 0.42 | 0.35 | 0.29 | 0.19 |
| EBITDA
| 698.282 | 912.572 | 860.592 | 768.281 | 772.672 | 751.763 | 638.139 | 557.778 | 480.044 | 361.658 | 283.652 | 125.137 |
| EBITDA Ratio
| 0.458 | 0.527 | 0.553 | 0.584 | 0.539 | 0.497 | 0.504 | 0.514 | 0.495 | 0.475 | 0.462 | 0.376 |